ImmunityBio Stock Forecast, Price & News

ImmunityBio (NASDAQ:IBRX) Frequently Asked Questions

Is ImmunityBio a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ImmunityBio stock.
View analyst ratings for ImmunityBio or view top-rated stocks.

Are investors shorting ImmunityBio?

ImmunityBio saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 12,310,000 shares, an increase of 18.0% from the December 15th total of 10,430,000 shares. Based on an average trading volume of 1,490,000 shares, the days-to-cover ratio is presently 8.3 days. Approximately 15.3% of the company's stock are short sold.
View ImmunityBio's Short Interest.

What price target have analysts set for IBRX?

1 analysts have issued 12-month price targets for ImmunityBio's shares. Their forecasts range from $25.00 to $25.00. On average, they expect ImmunityBio's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 383.6% from the stock's current price.
View analysts' price targets for ImmunityBio or view top-rated stocks among Wall Street analysts.

Who are ImmunityBio's key executives?

ImmunityBio's management team includes the following people:

• Patrick Soon-Shiong, Executive Chairman & Global Chief Medical Officer
• Richard Adcock, Chief Executive Officer & Director (LinkedIn Profile)
• Leonard S. Sender, Chief Operating Officer
• David Sachs, Chief Financial Officer
• Barry J. Simon, Director & Chief Corporate Affairs Officer (LinkedIn Profile)

Who are some of ImmunityBio's key competitors?

Some companies that are related to ImmunityBio include Ginkgo Bioworks (DNA), Neurocrine Biosciences (NBIX), Novavax (NVAX), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Abcam (ABCM), Denali Therapeutics (DNLI), Ablynx (ABLYF), Fate Therapeutics (FATE), Kodiak Sciences (KOD), BioCryst Pharmaceuticals (BCRX) and Twist Bioscience (TWST).
View all of IBRX's competitors.

What is ImmunityBio's stock symbol?

ImmunityBio trades on the NASDAQ under the ticker symbol "IBRX."

Who are ImmunityBio's major shareholders?

ImmunityBio's stock is owned by many different institutional and retail investors. Top institutional investors include Sheets Smith Wealth Management (0.04%), Clearwater Capital Advisors LLC (0.04%), Allspring Global Investments Holdings LLC (0.03%), Russell Investments Group Ltd. (0.03%) and Liberty One Investment Management LLC (0.01%). Company insiders that own ImmunityBio stock include Barry J Simon, Cheryl Cohen and Richard Adcock.
View institutional ownership trends for ImmunityBio.

Which major investors are selling ImmunityBio stock?

IBRX stock was sold by a variety of institutional investors in the last quarter, including Clearwater Capital Advisors LLC. Company insiders that have sold ImmunityBio company stock in the last year include Barry J Simon, and Cheryl Cohen.
View insider buying and selling activity for ImmunityBio or view top insider-selling stocks.

Which major investors are buying ImmunityBio stock?

IBRX stock was acquired by a variety of institutional investors in the last quarter, including Allspring Global Investments Holdings LLC, Liberty One Investment Management LLC, Russell Investments Group Ltd., and Sheets Smith Wealth Management.
View insider buying and selling activity for ImmunityBio or or view top insider-buying stocks.

How do I buy shares of ImmunityBio?

Shares of IBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunityBio's stock price today?

One share of IBRX stock can currently be purchased for approximately $5.17.

How much money does ImmunityBio make?

ImmunityBio has a market capitalization of $2.06 billion and generates $110 thousand in revenue each year.

How many employees does ImmunityBio have?

ImmunityBio employs 171 workers across the globe.

What is ImmunityBio's official website?

The official website for ImmunityBio is immunitybio.com.

Where are ImmunityBio's headquarters?

ImmunityBio is headquartered at 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121.

How can I contact ImmunityBio?

ImmunityBio's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The company can be reached via phone at (844) 696-5235 or via email at [email protected].